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Abstract
Objective—To determine rates of axillary dissection (ALND) and nodal recurrence in patients 
eligible for ACOSOG Z0011.
Summary Background Data—Z0011 demonstrated that patients with cT1-2N0 breast cancers 
and 1–2 involved sentinel lymph nodes (SLNs) having breast-conserving therapy (BCT) had no 
difference in locoregional recurrence or survival after SLN biopsy alone or ALND. The 
generalizability of the results and importance of nodal radiotherapy (RT) is unclear.
Methods—Patients eligible for Z0011had SLN biopsy alone. Prospectively defined indications 
for ALND were metastases in ≥3 SLNs or gross extracapsular extension. Axillary imaging was not 
routine. SLN and ALND groups and radiation fields were compared with chi-square and t-tests. 
Cumulative incidence of recurrences was estimated with competing risk analysis.
Results—From 8/2010–12/2016, 793 patients met Z0011 eligibility criteria and had SLN 
metastases. 130 (16%) had ALND; ALND did not vary based on age, estrogen receptor, 
progesterone receptor, or HER2 status. 5-year event-free survival after SLN alone is 93% with no 
isolated axillary recurrences. Cumulative 5-year rates of breast+nodal and nodal+distant 
recurrence were each 0.7%. In 484 SLN-only patients with known RT fields (103 prone, 280 
supine tangent, 101 breast+nodes) and follow-up≥12 months, the 5-year cumulative nodal 
recurrence rate was 1% and did not differ significantly by RT fields.
Conclusions—We confirm that even without preoperative axillary imaging or routine use of 
nodal RT, ALND can be avoided in a large majority of Z0011-eligible patients with excellent 
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regional control. This approach has the potential to spare substantial numbers of women the 
morbidity of ALND.
Introduction
Management of the breast cancer patient with clinically negative (cN0) axillary lymph nodes 
has evolved over the past 2 decades from the routine use of axillary lymph node dissection 
(ALND) to sentinel lymph node (SLN) biopsy alone, reserving ALND for those with 
positive SLNs.1 Management evolved further when the American College of Surgeons 
Oncology Group (ACOSOG) Z0011 trial demonstrated that ALND need not be routine for 
patients with positive SLN; 889 patients with cT1-2N0 breast cancers and 1–2 positive SLN 
treated by breast-conserving therapy (BCT) with whole breast irradiation (WBRT) were 
randomized to SLN biopsy alone vs ALND.2 At 6.3 years’ follow-up, there were no 
differences in nodal recurrence (< 1% in both arms) or in any category of survival.3 Z0011 
was practice-changing but generated controversy. Critics suggested that these results may 
not be widely applicable and that the Z0011 patients were not representative of breast cancer 
patients as a whole because the majority of those enrolled were postmenopausal women with 
estrogen receptor (ER) positive cancers. There were also concerns that follow-up was 
insufficient, and that although Z0011 specified the use of tangent field irradiation alone, the 
low rates of nodal recurrence observed after SLNB alone were in part due to the use of nodal 
RT in a proportion of the study patients.4, 5
Beginning in 2010, we prospectively applied the Z0011 eligibility criteria in our clinical 
practice to all cN0 patients undergoing BCT with planned WBRT. We have previously 
reported that among our first 287 Z0011-eligible patients, 84% avoided ALND.6 Here we 
report our expanded series of 793 consecutive Z0011 patients, focusing on the rate of ALND 
and on locoregional outcomes, stratified by type of RT.
Methods
In August 2010 we began to apply the results of ACOSOG Z0011 to the management of the 
axilla at Memorial Sloan Kettering Cancer Center. Women with cT1-2N0 invasive breast 
cancers undergoing BCT and having 1–2 positive SLN by routine hematoxylin and eosin 
(H&E) staining had SLNB only. Indications for ALND were prospectively defined as 
metastases in 3 or more SLN, matted nodes, or nodes with gross extracapsular extension.
Preoperative axillary imaging was not routine. If axillary imaging prior to referral showed 
that 1–2 nodes were abnormal, needle biopsy was not performed. When ≥ 3 abnormal nodes, 
were seen, a fine needle aspiration (FNA) of the most suspicious node was performed and, if 
malignant, ALND was performed. Patients with cN0 disease but biopsy-proven nodal 
metastases were managed with SLN biopsy as above, and have been reported previously.7 
Intraoperative SLN frozen section was eliminated, and patients were advised that a second 
surgery for ALND might be necessary. Management no longer employed the Memorial 
Sloan Kettering Cancer Center (MSKCC) nomogram to estimate the risk of additional 
positive nodes after SLNB.8 We anticipated that all patients would receive the adjuvant 
systemic therapy and WBRT that are part of standard care for node-positive patients 
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undergoing BCT. ALND remained standard management for SLN-positive patients 
undergoing mastectomy, and those with palpable nodal metastases. To mirror the Z0011 
eligibility criteria, we excluded all patients receiving neoadjuvant therapy and all patients 
with nodal disease detected only by immunohistochemistry. This study was approved by the 
MSKCC Institutional Review Board.
We prospectively collected clinical and demographic data for all eligible patients treated by 
14 different breast surgeons during the study period. Positive ER and progesterone (PR) 
receptor were defined as the presence of staining in ≥ 1% of tumor cells. HER2 positivity 
was defined as 3+ staining by immunohistochemistry and/or a FISH ratio > 2. Data on RT 
fields were obtained from radiation treatment summaries and/or port films. Nodal RT was 
defined as inclusion of the ipsilateral level III axillary and supraclavicular nodes, with or 
without internal mammary nodes, within the portals.
Chi-square tests and t-tests were used to compare characteristics of the SLN and ALND 
groups and radiotherapy fields. Competing risk analysis was used to estimate the cumulative 
incidence of distant, breast + nodal, breast only, and nodal + distant recurrences from the 
time of surgery.9 All statistical analysis was performed with SAS 9.4 (SAS Institute, Cary, 
NC) and R 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria) statistical 
software. P-values were 2 sided, and values of < 0.05 were considered significant.
Results
From August 2010 through December 2016, 793 patients met Z0011 eligibility criteria, had 
BCT, and had SLN metastases. Patient characteristics are summarized in Table 1. The 
median patient age was 58 years, the median clinical tumor size was 1.7 cm, and 84% of 
patients had hormone receptor positive, HER2 negative cancers. Systemic adjuvant therapy 
was given to 97% of patients and RT to 94%. Median follow-up for the entire cohort is 29 
months (range 2–76).
130 (16%) patients had ALND, most commonly for metastases in ≥ 3 sentinel nodes (n = 
88) or for SLN with extracapsular tumor extension (n = 34). Surgeon/patient preference 
accounted for ALND in 8 patients otherwise eligible for SLNB alone, with 6 of these 8 in 
our initial 2 years’ experience. One or more “high-risk” features, defined as age < 50 years, 
HER2 positive, or triple negative breast cancer were present in 288 patients. The remaining 
505 patients were age 50 or older with hormone receptor positive, HER2 negative cancers. 
The frequency of ALND did not differ significantly for the “high-risk” and non-high risk 
groups, 16% vs 17%, respectively (p = 0.81).
In comparing the patients who had ALND and those who did not (Table 1), there were no 
significant differences in age, tumor histology, tumor grade, or biologic subtype (as 
approximated by ER, PR, and HER2 status). Patients requiring ALND had significantly 
larger tumors (2.2 versus 1.6 cm, p < 0.0001) and were significantly more likely to have 
SLNs with microscopic extracapsular tumor extension (82% versus 31%, p < 0.0001). More 
patients in the ALND group received chemotherapy plus endocrine therapy, and fewer 
received endocrine therapy alone, reflecting their higher risk for distant recurrence (p = 
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0.001). Only 3% of patients in each group did not receive some form of systemic therapy. 
There were no differences between groups in the use of RT (p = 0.13).
The 5-year event-free survival for the SLNB-only group is 93% (95% confidence interval 
[CI] 89%–94%) There have been no first-event (isolated) axillary recurrences. Among 8 
nodal recurrences, 4 were coincident with ipsilateral breast tumor recurrence and 4 were 
synchronous with distant metastases. Among the 4 patients with breast and axillary nodal 
recurrence, 3 had not received radiotherapy and the median time to recurrence was 9.5 
months (range 3–27). Among the 4 patients with nodal and distant recurrence, 1 was 
axillary, 2 were supraclavicular, and 1 was supraclavicular and internal mammary. The 
cumulative incidence of recurrence by type of event is shown in Figure 1. Distant recurrence 
was the most common and had a 5-year cumulative incidence of 5% (95% CI 3%–7%). The 
median time to distant recurrence was 18.5 months (n=24, range 1–67 months). The 5-year 
cumulative rates of breast + nodal, and nodal + distant recurrences were 0.7% (95% CI 0–
1%) and 0.7% (95% CI 0–2%), respectively, with a median time to any nodal recurrence of 
25 months (n= 8, range 3–67months). The 5-year rate of breast-only recurrences was 1.6% 
(95% CI 0–3%). At last follow-up, 746 patients (94%) were alive and free of breast cancer, 
18 were alive with metastatic breast cancer, 11 had died of breast cancer, 7 were alive with 
other cancers, 6 had died of other cancer while free of breast cancer, and 5 were dead of an 
unknown cause.
To better stratify the risk of nodal recurrence, we examined a subset of 509 patients treated 
with SLNB alone with known RT fields and follow-up of at least 12 months. We excluded 
25 who received non-standard treatment (23 with no RT and 2 with partial breast RT), 
leaving 484 for analysis. Of these, 103 (21%) had prone breast RT, 280 (58%) had supine 
tangent breast RT, and 101 (21%) received breast and nodal RT. Patients selected for nodal 
RT had more high-risk features than those treated prone or with tangent fields alone (Table 
2). At a median follow-up of 37 months (range 12–75) there have been 5 nodal recurrences 
among this subset; 4 nodal and distant and 1 breast and axillary. The 5-year cumulative rate 
of nodal recurrence was 1% (95% CI 0–2%) and did not differ significantly by RT fields 
(Table 2). Nodal recurrence was seen in 1% of patients treated prone, 1.4% of those treated 
supine, and in none of those receiving breast + nodal RT.
Discussion
Here we demonstrate in a large series of patients, selected only on the basis of Z0011 
eligibility criteria, that the morbidity of ALND was avoided in 84%. The results of 
retrospective studies which have addressed this question, summarized in Table 3, vary 
widely, with ALND avoided in 9–75% of patients.5, 10–13 This variation is not at all 
surprising, as these studies vary by denominator (all patients vs all node-positive patients vs 
all node-positive patients having BCT), by operation (SLNB versus ALND), and by the 
failure to distinguish between SLN and non-SLN metastases. The Z0011 eligibility criteria 
for omission of ALND specified metastases in ≤ 2 SLN and since additional nodal 
metastases were found in 27% of patients randomized to ALND, it can be assumed that an 
equal number of patients randomized to the SLNB-only arm had additional axillary 
metastases which were successfully controlled without further surgery.3 Retrospective 
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studies which do not distinguish between metastases in the SLN and the non-SLN minimize 
the potential benefit of adopting the Z0011 approach.
Some controversy surrounds the subject of preoperative axillary imaging, which we have 
elected not to do in our Z0011-eligible patients. Among 425 of our Z0011-eligible patients 
with abnormal axillary imaging (on mammography, ultrasound, or MRI) 70% had 1–2 
positive nodes and could avoid ALND.14 Among 141 of our Z0011-eligible patients with a 
positive image-guided axillary needle biopsy, 47% had 1–2 positive nodes and could avoid 
ALND.7 These data confirm that preoperative axillary imaging and even a positive axillary 
needle biopsy are inadequate to make the decision for ALND, and that for Z0011-eligible 
patients, a negative clinical examination of the axilla is sufficient.
In our prospective study of Z0011-eligible patients, only the number of SLN metastases or 
extracapsular extension could be considered in the decision to perform ALND, and we did 
not apply any additional “high-risk” selection criteria such as patient age, ER status, or 
HER2 status. This decision was based on previous studies which found that nodal recurrence 
after ALND was not related to patient age or hormone receptor status.15, 16 Our results 
support that decision; although our study, like Z0011, largely comprised patients who were 
older and ER positive, the rate of ALND was no higher among patients who were “high 
risk” by younger age and/or ER negative and/or HER2 positive disease. These results 
confirm previous work demonstrating that patients at higher risk for systemic relapse do not 
necessarily have a heavier nodal disease burden.17, 18 These results are also consistent with 
the 10-year outcomes of the Z0011 trial, in which younger age and ER negativity were 
significantly associated with locoregional recurrence, but event rates did not differ between 
the ALND and SLNB-only arms, and the majority of the locoregional events were ipsilateral 
breast, not nodal, recurrences.3 Further, an exploratory analysis of Z0011 has found no 
differences in 10-year overall survival by ER status or by axillary treatment.19
To what extent did node field RT contribute to the excellent locoregional control of Z0011? 
Although the Z0011 protocol specified RT to breast only, an audit by Jagsi et al.20 of a 
subset of Z0011 patients for whom complete RT data were available found that 19% 
received nodal RT and that nodal RT was equally frequent in the ALND and SLNB-only 
arms. Like Z0011, 21% of our patients received nodal RT, and the use of nodal RT increased 
with the number of positive SLNs. Risk factors for local recurrence, including extracapsular 
extension, lymphovascular invasion, and larger tumor size were more common among our 
patients receiving nodal RT. Of note, our patients treated by WBRT without nodal RT were 
not a uniquely favorable subgroup: about half had lymphovascular invasion and 17% (prone 
RT) to 28% (supine tangent RT) had microscopic extracapsular tumor extension in their 
SLN, despite which nodal recurrence of any type (isolated or combined) was rare. Although 
the AMAROS trial21 demonstrated that locoregional recurrence and survival did not differ 
among patients with 1–2 SLN metastases randomized to nodal RT versus ALND, the results 
of ACOSOG Z0011 and our own study strongly suggest that routine nodal RT for SLN-
positive patients treated with SLNB alone need not be mandatory.
To our knowledge, this is the first confirmation of the findings of ACOSOG Z0011 in 
clinical practice and indicates that nodal recurrence rates are extremely low despite relatively 
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infrequent use of nodal RT. The strengths of this study include its large patient population, 
prospective design, uniform treatment algorithm, and detailed information regarding the use 
of systemic therapy and RT fields. Moreover, the similar frequencies of nodal RT use in our 
study (21%) and ACOSOG Z0011(19%) indicate that radiation oncology practices between 
the two studies were similar. Our study has some limitations. Single-institution data from a 
group of high-volume breast surgeons may not be widely representative, but given that our 
results mirror those of ACOSOG Z0011 (in which participant surgeons varied widely by 
geography and case volume), we do not think that this is a major limitation. Our median 
follow-up of 3 years (used to calculate rates of nodal recurrence) is relatively short, but since 
the median time to regional node recurrence in the ACOSOG Z0011 trial was 4 years and 
only a single nodal recurrence was observed after 76 months,3 we are highly unlikely to 
observe a substantial increase in isolated nodal recurrences with further follow-up. Finally, 
we must emphasize that our results cannot be extrapolated beyond the Z0011 selection 
criteria (cT1-2N0, BCT, 1–2 SLN+, WBRT, systemic therapy). New trials are asking 
whether ALND can be avoided for SLN-positive patients treated by mastectomy4 or for 
patients who are SLN-positive after neoadjuvant chemotherapy,22 and it remains unclear if 
ALND can be avoided for SLN-positive patients treated with partial breast RT or with no RT 
at all. For these patients, a positive SLN remains at present an indication for ALND.
Conclusions
Here we confirm the findings of ACOSOG Z0011 in a large prospective study, and 
demonstrate that without preoperative axillary imaging, the use of additional selection 
criteria, or routine use of nodal RT, ALND can be avoided in a substantial majority of 
Z0011-eligible breast cancer patients with excellent local, regional, and distant control of 
disease. Wider adoption of the ACOSOG Z0011 algorithm has the potential to spare a 
substantial number of women the morbidity of ALND.
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Figure 1. 
Cumulative incidence by type of event (whole dataset, n = 793)
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Table 1
Patient characteristics
Characteristic Total ALND No ALND (SLNB only)
(n = 793) (n = 130) (n = 663) p-value
Age (median, range) 58 years (30–92) 57 years (35–86) 58 years (30–92) 0.87
Clinical tumor size (median, range)—from imaging 1.7 cm (.2–6.5) 2.0 cm (.6–6.5) 1.6 cm (.2–6) 0.01
Histology 0.32
 Ductal 689 (87%) 108 (83%) 581 (88%)
 Lobular 71 (9%) 16 (12%) 55 (8%)
 Mixed D&L 27 (3%) 4 (3%) 23 (3%)
 Other (metaplastic, mucinous) 6 (0.8%) 2 (2%) 4 (0.6%)
Grade 0.57
 1 39 (5%) 5 (4%) 34 (5%)
 2 440 (55%) 69 (53%) 371 (56%)
 3 305 (38%) 55 (42%) 250 (38%)
Unknown 10 (1%) 1 (1%) 8 (1%)
Subtype 0.18
 ER or PR+/HER2− 668 (84%) 110 (85%) 558 (84%)
 ER or PR+/HER2+ 59 (7%) 10 (8%) 49 (7%)
 ER PR−/HER2+ 20 (3%) 0 (0%) 20 (3%)
 Triple negative 46 (6%) 10 (8%) 36 (5%)
No. positive SLNs (median, range) 1 (1–11) 3 (1–11) 1 (1–2) <.0001
LVI present 464 (59%) 84 (65%) 380 (57%) 0.12
ECE* <.0001
 None 483 (61%) 23 (18%) 460 (69%)
 ≤ 2 mm 141 (18%) 28 (14%) 113 (17%)
 > 2 mm 169 (21%) 79 (61%) 90 (14%)
Path T Stage <.0001
 1 504 (64%) 56 (43%) 448 (68%)
 2 286 (36%) 73 (56%) 213 (32%)
 3 3 (0%) 1 (0%) 2 (0%)
Path Tumor Size (median, range) 1.7 cm (.1–5.7) 2.2 cm (.4–5.7) 1.6 cm (.1–5.2) <.0001
Path Stage <.0001
 1 129 (16%) 0 (0%) 129 (19%)
 2 592 (75%) 60 (46%) 532 (80%)
 3 72 (9%) 70 (54%) 2 (0%)
Adjuvant Tx 0.001
 No chemo or endo 17 (2%) 3 (2%) 14 (2%)
 Chemo + endocrine 513 (65%) 101 (78%) 412 (62%)
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Characteristic Total ALND No ALND (SLNB only)
(n = 793) (n = 130) (n = 663) p-value
 Chemo only 73 (9%) 12 (9%) 61 (9%)
 Endocrine only 186 (23%) 13 (10%) 173 (26%)
 Unknown chemo/endo 4 (0%) 1 (1%) 3 (0%)
RT 743 (94%) 118 (91%) 625 (94%) 0.13
 No RT 45 (6%) 11 (8%) 34 (5%)
 Unknown RT 5 (1%) 1 (0%) 4 (1%)
ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; ER, estrogen receptor; PR, progesterone receptor; SLN, sentinel lymph 
node; LVI, lymphovascular invasion; ECE, extracapsular extension; RT; radiation therapy
Note: p-values are based on complete data.
*
missing 10
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Table 2
Patient characteristics by radiotherapy fields
Radiation therapy (n = 484)
Prone breast Supine breast Breast + nodes p-value
# patients (%) 103 (21%) 280 (58%) 101 (21%)
Age (median) 55 58 56 0.28
pT size (cm; median) 1.5 1.6 1.8 0.08
# SLN+ (median) 1 1 1 0.0004
LVI present (%) 50 (49%) 157 (56%) 73 (72%) 0.002
ECE present (%)* 19 (18%) 75 (27%) 55 (54%) <.0001
Stage > 2A 26 (25%) 87 (31%) 41 (41%) 0.06
nodal relapse # (%) 1 (1%) 4 (1.4%) 0
.544**
pT, primary tumor; SLN, sentinel lymph node; LVI, lymphovascular invasion; ECE, extracapsular extension;
*Uses all categories of ECE size
**Gray’s test
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Table 3
Elimination of axillary lymph node dissection using ACOSOG Z011 eligibility criteria
Author Number of Patients No ALND
Ngui11 119 22%
Verhuevel12 916 61%
Delpech10 125 70%
Yi13 488 75%
Guth5 55 9%
Present Study 793 84%
ACOSOG, American College of Surgeons Oncology Group
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